Mablink Bioscience is a biopharmaceutical company based in Lyon, France, focused on developing antibody-drug conjugates. The company has developed PSARlink™, an innovative and hydrophilic drug-linker technology designed to improve the pharmacological properties of ADCs. Led by CEO Jean-Guillaume Lafay, Mablink completed a €4M seed financing to support its programs. The proceeds from the seed round will be used to advance its ADC pipeline. The article identifies the financing as a seed round and does not detail other financial instruments or prior fundraising rounds.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Apr 2021